Obesity, Visceral Clinical Trial
Official title:
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
This study is a clinical study to investigate the gluconeogenesis pathway related to visceral adipose tissue (VAT) in obese individuals without type 2 diabetes and the effects of empagliflozin (EMPA) on glucose homeostasis in viscerally-obese individuals using functional studies of glycerol metabolism in hepatic gluconeogenesis using a well-validated nuclear magnetic resonance (NMR) spectroscopy platform.
Diabetes mellitus type II is the consequence of insulin resistance and pancreatic beta cell
failure resulting from a variety of metabolic insults, one of which is excess body
adiposity/obesity. In the diabetic individual, hepatic gluconeogenesis may go uninhibited due
to failure of the body's normal feedback mechanisms to appropriately incorporate glucose into
cells via insulin signaling, leading to excess gluconeogenesis and hyperglycemia. The
substrate for this excess glucose derives from multiple sources in the liver including
dietary glycerol, adipose-derived glycerol from lipolysis, and substrates from the citric
acid cycle. In the normal state, lipolysis is maintained at a steady state in equilibrium
between stored dietary triglycerides and free fatty acids. However, in situations of
triglyceride excess (e.g. in the obese state), lipolysis may become overactive resulting in
increased free fatty acids and adipose-derived glycerol. This excess glycerol drives hepatic
gluconeogenesis and is incorporated into glucose and released into the blood, leading to
hyperglycemia, and ultimately diabetes and its clinical sequelae.
A popular hypothesis linking visceral fat with excess gluconeogenesis is delivery of glycerol
arising from mesenteric triglyceride turnover directly into the portal circulation and to the
liver. Glycerol is a primary substrate for gluconeogenesis in the liver. Under normal
conditions, hepatic gluconeogenesis begins from glycerol ingested in the diet which is
converted to glycerol-3-phosphate and subsequently dihydroxyacetone phosphate (DHAP) in the
liver. DHAP is converted to fructose-1,6-bisphosphate which undergoes a series of reactions
to become a single 6-carbon glucose molecule. Adipocytes contribute glycerol to hepatic
gluconeogenesis through lipolysis of triglyceride stores. Although glycerol-gluconeogenesis
has been extensively studied in animals, the traditional reliance on radioactive tracers
makes translation to humans difficult for many reasons. We aim to use new techniques to
explore the mechanisms behind altered glucose metabolism related to excess visceral adiposity
in obese adults by quantifying the relative contributions of varying substrates to
liver-derived glucose. One such method uses 13C3 labeled glycerol to trace the incorporation
of glycerol from dietary sources to hepatic gluconeogenesis. This technology utilizes nuclear
magnetic resonance (NMR) spectroscopy, a technique that does not require ionizing radiation
and has been extensively validated, to analyze the NMR spectra of plasma glucose and quantify
the "percent enrichment" of the circulating glucose molecules with labeled glycerol. In turn,
differences in enrichment reflect variability in hepatic glucose metabolism as it relates to
the contribution of glycerol from visceral adipose tissue to gluconeogenesis.
The rationale of this project is to utilize existing technology to investigate the impact of
excess visceral adiposity on glycerol metabolism in hepatic gluconeogenesis in obese adults
without diabetes and to explore the effects of treatment with EMPA on visceral adiposity
related glucose homeostasis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04807959 -
Evaluation of the Effectiveness of a Comprehensive Visceral Adiposity-Focused Anti-Obesity Program
|
||
Completed |
NCT06377358 -
Study of Lipolysis of Visceral Reserve Fat Using Tecar Therapy.
|
N/A | |
Completed |
NCT04754464 -
Clinical Study on the Effect of a Synbiotic on Body Fat Mass
|
N/A | |
Not yet recruiting |
NCT04942093 -
NUTritional Impact of a Hypocaloric Hyperprotein Diet Before Obesity Surgery
|
N/A | |
Completed |
NCT03239782 -
The "Metabolically-obese Normal-weight" Phenotype and Its Reversal by Calorie Restriction
|
N/A | |
Completed |
NCT06158191 -
Long-term Benefits of Abdominal Fat Loss in Abdominally Obese Dyslipidemic Patients (SYNERGIE Study)
|
N/A | |
Recruiting |
NCT04100616 -
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Obesity
|
||
Completed |
NCT04780828 -
Investigation of the Effects of Different Levels of Obesity on the Respiratory System
|
||
Completed |
NCT05895916 -
Extreme Exercise and Energy Expenditure (4E) Study
|
N/A | |
Completed |
NCT04436419 -
Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study
|
N/A | |
Completed |
NCT03038620 -
Impact of Liraglutide 3.0 on Body Fat Distribution
|
Phase 4 | |
Completed |
NCT04255173 -
Anthropometric And Body Composition Measurements Related To Osteoporosis In Geriatric Population
|
N/A | |
Completed |
NCT04592107 -
The Association of Visceral Adiposity Index With Progression of Chronic Kidney Disease
|
||
Completed |
NCT03542864 -
Medical Supervised Duodenal-Enteral Feeding Treatment
|
N/A | |
Completed |
NCT05789888 -
Genes Variability in Obesity and Normal Body Weight Patients.
|